Definition: Pruritus or itch in EGFRI-treated patients is due to the Acneiform rash or to the Xerosis or eczema.1

Incidence: Very common2,3,4,5,6

Onset: Concomitantly with acneiform eruption and/or Xerosis/eczema.

Resolution: Within 4 weeks of completion of EGFRI treatment.

ICD10 codes:

  • L29.8 Other specified Pruritus.
  • Y43.8 Other drugs, medicaments and biological primarily systemic substances causing adverse effects in therapeutic use, not elsewhere classified.

Grade 1

Mild or localised; topical intervention indicated.

Grade 2

Intense or widespread; intermittent; skin changes from scratching (eg oedema, papulation, Excoriations, Lichenification, oozing/Crusts); oral intervention indicated; limiting instrumental ADL (refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc).

Grade 3

Intense or widespread; constant; limiting self care ADL (refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not confined to bed) or sleep; oral corticosteroid or immunosuppressive therapy indicated.

References

1Segaert S & Van Cutsem E. Ann Oncol 2005; 16: 1425-1433.
2European Medicine Agency. Tarceva® (erlotinib) Summary of Product Characteristics 2009.
3European Medicine Agency. Iressa® (gefitinib) Summary of Product Characteristics 2009.
4European Medicine Agency. Erbitux® (cetuximab) Summary of Product Characteristics 2009.
5European Medicine Agency. Vectibix® (panitumumab) Summary of Product Characteristics 2009.
6European Medicine Agency. Tyverb® (lapatinib) Summary of Product Characteristics 2010.

Page last updated in 2009.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings